Amprion and Modality.AI work together on biomarkers project

Amprion and Modality.AI have formed a collaboration to explore the combined use of molecular biomarkers and artificial intelligence-enabled digital assessments in neurodegenerative disease research. The companies aim to connect evidence of underlying disease biology with measurable changes in speech, cognition, facial expression and behaviour.

The partnership will combine Amprion’s seed amplification testing with Modality.AI’s browser-based Tina platform. Tina uses structured audiovisual conversations to generate objective measures of speech, language and cognition, allowing researchers to track functional changes through assessments conducted either at clinical sites or remotely.